All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The Psoriasis and Psoriatic Arthritis Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Psoriasis and Psoriatic Arthritis Hub cannot guarantee the accuracy of translated content. The Psoriasis and Psoriatic Arthritis Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Psoriasis and Psoriatic Arthritis Hub was pleased to speak to Steven R. Feldman, Wake Forest University, Winston-Salem, US. We asked, Why do we have low adherence to psoriasis treatments and how do we improve that?
Why do we have low adherence to psoriasis treatments and how do we improve that?
Feldman begins by pointing out that adherence to treatment is not the default and should not be assumed. It is then discussed how treatments can differ between localized and generalized psoriasis, and how doctors can increase treatment adherence in their patients.
Krim et al. conducted a population-based study within a cohort of 13 million births to evaluate the association between psoriasis in pregnancy and maternal and neonatal outcomes. Here, we summarize key findings...
At the 2022 EADV Congress, Mockenhaupt presented safety data from five clinical trials investigating spesolimab. Here we summarize this presentation.
Subscribe to get the best content related to psoriasis and psoriatic arthritis delivered to your inbox